Forster, MD, Forget, F, Murillo, SM, García-Fructuoso, I, Ibrahim, NK, Marathe, O, Kristensen, CA, Laban, S, Metcalf, R, Majem, M, Peguero, JA, Wildiers, H, Marmé, F, Brana, I, Mueller, C, Brignone, C, Triebel, F. Impact of eftilagimod alfa, an APC activator via MHC class II, on lymphocyte activation and survival outcomes in metastatic cancer patients.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.2569. PMID:. IF:41.900(Q1/1D).

Crous, C, de Herreros, MG, Torras, OR, Jimenez, N, Ferrer-Mileo, L, Garcia-Esteve, S, Rodriguez, L, Altamirano, M, Salinas, B, Cobo-Lopez, S, Fernandez-Mañas, L, Duran, MAC, Pous, AF, Chirivella, I, Figols, M, Costa, SC, Rodriguez-Vida, A, Anguera, G, González, NS, Mellado, B. Clinical impact and molecular profiling of PTEN loss and TMPRSS2:ERG fusion in metastatic hormone-sensitive prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5101. PMID:. IF:41.900(Q1/1D).

Macia, S, Aladid, RL, Tovar, R, Garmendia, L, Lillo, CP, Fossati, M, Romero, ML, Selles, AN, Castellano, D, Gonzalezbilla, E, Maroto-Rey, JP, Piulats, JM, Lista, AGD, Parente, P. Explainable machine learning for continuous transcriptomic modeling of metastatic risk in prostate cancer (MET-score).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.5129. PMID:. IF:41.900(Q1/1D).

Alvarez, RMA, Hindi, N, Carrasco-Garcia, I, Sanfilippo, R, Sebio, A, Redondo, A, Alvarez, A, Morosi, C, Romagosa, C, Artigas, V, Casares, CM, Asencio, JM, Guzmán-Gómez, L, González-Lopez, J, Belinchon, B, Sangalli, C, Gutierrez, A, Jurado, JC, Broto, JM, Gronchi, A. Trabectedin with concomitant radiotherapy in resectable retroperitoneal L-sarcoma: A multicenter, prospective, phase I/II trial-A collaborative study by the Spanish (GEIS), Italian (ISG), and French (FSG) groups.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11507. PMID:. IF:41.900(Q1/1D).

Moura, DS, Mondaza-Hernandez, JL, Shirikova, A, Romero-Gonzalez, P, Carrera, M, Rodriguez, C, Martínez-Trufero, J, Sebio, A, Jurado, JC, Valverde, C, Beveridge, RD, Carrasco-Garcia, I, Gonzalez-Billalabeitia, E, Fernandez-Jara, J, Lopez-Jimenez, C, Hindi, N, Gutierrez, A, Broto, JM. Prognostic significance of HMGB1 expression as a biomarker of immunogenic cell death in patients with leiomyosarcoma and undifferentiated pleomorphic sarcoma treated with chemo-immuno-based regimens. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23526. PMID:. IF:41.900(Q1/1D).

Gelderblom, H, Wang, V, Doherty, M, Sebio, A, Stacchiotti, S, Wilky, BA, Blay, JY, Brohl, AS, Morales, CMV, Reichardt, P, Martin-Broto, J, Davis, EJ, De Haan, JJ, O'Neill, B, Babcock, E, Garcia, J, Senne, L, Shepard, D, Chawla, SP, Jones, RL. The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11504. PMID:. IF:41.900(Q1/1D).